About
About Shenzhen Chipscreen Biosciences Co., Ltd
Shenzhen Chipscreen Biosciences Co., Ltd. engages in the pharmaceutical industry in China. The company develops Chidamide, a subtype-selective histone deacetylase inhibitor for peripheral T-cell lymphoma, breast cancer, and diffuse large B-cell lymphoma indications; Chiglitazar, a PPAR full agonist for diabetes treatment; Siglitazone for metabolism treatment area; and Cioronib, a novel molecular, which selectively inhibits tumor-related protein kinase targets. It is also involved in the development of CS23546, a small molecule PD-L1 inhibitor, which relieves the immunosuppressive activity mediated by the PD-1/PD-L1 signaling pathway; CS231295, a brain-penetrating selective Aurora B inhibitor; and CS32582, a small-molecule allosteric inhibitor of tyrosine kinase 2. In addition, the company develops CS08399, a potential brain-penetrating PRMT5-MTA inhibitor for BIC; CS12088, a hepatitis B nucleocapsid assembly modulator; and CS12192, a highly selective JAK3 kinase inhibitor. Shenzhen Chipscreen Biosciences Co., Ltd. was founded in 2001 and is headquartered in Shenzhen, China.
Visit company website
5 years, 5 months ago
Shenzhen Chipscreen Biosciences Co., Ltd is currently in a long term uptrend where the price is trading 4.9% above its 200 day moving average.
From a valuation standpoint, the stock is 499.1% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 57.7.
Shenzhen Chipscreen Biosciences Co., Ltd's total revenue rose by 84.5% to $83M since the same quarter in the previous year.
Its net income has dropped by 424.1% to $-7M since the same quarter in the previous year.
Finally, its free cash flow fell by 146.4% to $-97M since the same quarter in the previous year.
Based on the above factors, Shenzhen Chipscreen Biosciences Co., Ltd gets an overall score of 2/5.